Breadcrumb

[A16-39] Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2016-06-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 283 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G15-07] Ibrutinib (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Withdrawn commission

[G14-11] Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed

[A16-72] Ibrutinib (chronic lymphocytic leukaemia) - Addendum to Commission A16-39
Status: Commission completed

[A16-60] Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-04] Ibrutinib - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-10-04 Extract of dossier assessment 283 kBPDFdownload file
2016-10-04 Dossier assessment (German version) 591 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V [PDF, 283 kB]

Federal Joint Committee (G-BA)

2016-12-15 A G-BA decision was published.

G-BA documents on this decision

Press releases

2016-10-04 Ibrutinib in CLL: added benefit for treatment-naive patients not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close